Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) Shares Outstanding (Diluted Average) (2020 - 2024)

Historic Shares Outstanding (Diluted Average) for Evogene (EVGN) over the last 10 years, with Q4 2024 value amounting to $5.7 million.

  • Evogene's Shares Outstanding (Diluted Average) rose 2413.96% to $5.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.7 million, marking a year-over-year increase of 2413.96%. This contributed to the annual value of $5.7 million for FY2024, which is 2413.96% up from last year.
  • As of Q4 2024, Evogene's Shares Outstanding (Diluted Average) stood at $5.7 million, which was up 2413.96% from $1820.0 recorded in Q2 2024.
  • In the past 5 years, Evogene's Shares Outstanding (Diluted Average) ranged from a high of $40.4 million in Q4 2021 and a low of $420.0 during Q2 2022
  • For the 5-year period, Evogene's Shares Outstanding (Diluted Average) averaged around $10.4 million, with its median value being $4.4 million (2022).
  • In the last 5 years, Evogene's Shares Outstanding (Diluted Average) tumbled by 8975.64% in 2022 and then skyrocketed by 65714.29% in 2023.
  • Evogene's Shares Outstanding (Diluted Average) (Quarter) stood at $28.2 million in 2020, then soared by 43.59% to $40.4 million in 2021, then plummeted by 89.76% to $4.1 million in 2022, then rose by 10.81% to $4.6 million in 2023, then rose by 24.14% to $5.7 million in 2024.
  • Its last three reported values are $5.7 million in Q4 2024, $1820.0 for Q2 2024, and $4.6 million during Q4 2023.